Comparative safety of newer oral antidiabetic drugs

Bibliography

• GOLDSTEIN BJ, MÜLLER-WIELAND D: Textbook Of Type 2 Diabetes, Martin Dunitz (Ed), London, UK (2003).
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
   PubMed Web of Science ®Google Scholar
• KRENTZ AJ, BAILEY CJ: Type 2 Diabetes In Practice (2nd edn), Royal Society of Medicine Press, London, UK (2005).
   Google Scholar
• KRENTZ AJ, BAILEY CJ: Drug treatment of Type 2 diabetes. Drugs (2005) 65:385-411.
   PubMed Web of Science ®Google Scholar
• EVANS AJ, KRENTZ AJ: Glimepiride – a new sulphonylurea. Prescriber (1999) 10:51-58.
   Google Scholar
• RENDELL M: The role of sulphonylureas in the management of Type 2 diabetes mellitus. Drugs (2004) 64:1339-1658.
   PubMed Web of Science ®Google Scholar
• SELTZER HS: A summary of criticisms of the findings and conclusions of the University Group Diabetes Program. Diabetes (1972) 21:976-979.
   PubMed Web of Science ®Google Scholar
• KRENTZ AJ: Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study. Proceedings of the VIIIth European Symposium on Metabolism. Amsterdam, The Netherlands, Elsevier Science International Congress Series (2003) 1253:261-277.
   Google Scholar
• SIMPSON SH, MAJUMDAR SR, TSUYUKI RT, EURICH DT, JOHNSON JA: Dose-response relation between sulfonylurea drugs and mortality in Type 2 diabetes mellitus: a population-based cohort study. CMAJ (2006) 174:169-174.
   PubMed Web of Science ®Google Scholar
• KRENTZ AJ, FERNER RE, BAILEY CJ: Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. (1994) 11:223-241.
   PubMed Web of Science ®Google Scholar
• MASSI-BENEDETTI M: Glimepiride in Type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin. Ther. (2003) 25:799-816.
   PubMed Web of Science ®Google Scholar
• THISTED H, JOHNSEN SP, RUNGBY J: Sulfonylureas and the risk of myocardial infarction. Metabolism (2006) 55(5 Suppl. 1):S16-S19.
   PubMed Web of Science ®Google Scholar
• GRIBBLE FM, REIMANN F: Pharmacological modulation of KATP channels. Biochem. Soc. Trans. (2002) 30:333-339.
   PubMed Web of Science ®Google Scholar
• WILSON SH, KENNEDY FP, GARRAT KN: Optimisation of the management of patients with coronary heart disease and Type 2 diabetes mellitus. Drugs Aging (2001) 18:325-333.
   PubMed Web of Science ®Google Scholar
• SCHERNTHANER G, GRIMALDI A, DIMARIO U et al.: GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in Type 2 diabetes. Eur. J. Clin. Invest. (2004) 34:535-542.
   PubMed Web of Science ®Google Scholar
• LANDGRAF R: Meglitinide analogues in the treatment of Type 2 diabetes mellitus. Drugs Aging (2000) 17:411-425.
   PubMed Web of Science ®Google Scholar
• DORNHORST A: Insulotropic meglitinide analogues. Lancet (2001) 358:1709-1715.
   PubMed Web of Science ®Google Scholar
• HASSLACHER C: MULTINATIONAL REPAGLINIDE RENAL STUDY GROUP: Safety and efficacy of repaglinide in Type 2 diabetic patients with and without impaired renal function. Diabetes Care (2003) 26:886-891.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE: α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. (1998) 6:132-145.
   Google Scholar
• HOLMAN RR, CULL CA, TURNER RC: A randomised double-blind trial of acarbose in Type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care (1999) 22:960-964.
   PubMed Web of Science ®Google Scholar
• CHIASSON JL, JOSSE RG, GOMIS R, HANEFELD M, KARASIK A, LAAKSO M: STOP-NIDDM Trial Research Group: Acarbose for the prevention of diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 359:2072-2077.
   PubMed Web of Science ®Google Scholar
• SCHEEN A: Is there a role for alpha-glucosidase inhibitors in the prevention of Type 2 diabetes mellitus? Drugs (2003) 63:933-951.
   PubMed Web of Science ®Google Scholar
• SCOTT LJ, SPENCER CM: Miglitol: a review of its therapeutic potential in Type 2 diabetes mellitus. Drugs (2000) 59:521-549.
   PubMed Web of Science ®Google Scholar
• ZHOU G, MYERS R, LI Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. (2001) 108:1167-1174.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854-865.
   PubMed Web of Science ®Google Scholar
• DAY C: Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med. (1999) 16:1-14.
   PubMed Web of Science ®Google Scholar
• COLCA JR, KLETZIEN RF: What has prevented the expansion of insulin sensitisers? Expert Opin. Investig. Drugs (2006) 15:205-210.
   PubMed Web of Science ®Google Scholar
• KRENTZ AJ, BAILEY CJ, MELANDER A: Thiazolidinediones for Type 2 diabetes. Br. Med. J. (2000) 321:252-253.
   PubMed Web of Science ®Google Scholar
• YKI-JÄRVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 351:1106-1118.
   PubMed Web of Science ®Google Scholar
• SEMPLE RK, CHATERJEE KK, O’RAHILLY S: PPARγ and human metabolic disease. J. Clin. Invest. (2006) 116:581-589.
   PubMed Web of Science ®Google Scholar
• LEBRASSEUR NK, KELLY M, TSAO TS et al.: Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. (2006) 291:E175-E181.
   PubMed Web of Science ®Google Scholar
• NESTO RW, BELL D, BONOW RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and the American Diabetes Association. Circulation (2003) 108:2941-2948.
   PubMed Web of Science ®Google Scholar
• IUORNO MJ, NESTLER J: Insulin-lowering drugs in polycystic ovary syndrome. Obset. Gynecol. Clin. North Am. (2001) 28:153-164.
   PubMed Web of Science ®Google Scholar
• MARTEN FMAC, VISSEREN FLJ, LEMAY J, DE KONING EJP, RABELINK TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs (2002) 62:1463-1480.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28:1547-1554.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) a randomised controlled trial. Lancet (2005) 366:1279-1289.
   PubMed Web of Science ®Google Scholar
• YKI-JÄRVINEN H: The PROactive study: some answers, many questions. Lancet (2005) 366:1241-1242.
   PubMed Web of Science ®Google Scholar
• The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 368:1096-1105.
   PubMed Web of Science ®Google Scholar
• ALI AA, WEINSTEIN RS, STEWART SA, PARFITT AM, MANGOLAS SC, JILKA RL: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2005) 146:1226-1235.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA (2005) 294:2581-2586.
   PubMed Web of Science ®Google Scholar
• TUOMILEHTO J, WAREHAM N: Glucose lowering and diabetes prevention: are they the same? Lancet (2006) (Epub ahead of print).
   Google Scholar